Thousandth patient enrolled in Stryker’s Trevo Retriever Registry


stryker_trevo_provue_main.jpgData from the first 500 patients enrolled in the Trevo Registry were presented at the European Stroke Organisation Conference (ESOC; 10-12 May, Barcelona, Spain) by Antonin Krajina (Hradec Kralove, Czech Republic).

The data showed that nine out of 10 patients had complete or near complete removal of the clot and over half were functionally independent. In a subset of these 500 patients, over 58% were functionally independent at 90 days. This closely matches the population of the interventional arm in a meta-analysis of randomised clinical trials for ischaemic stroke, according to a company release.

The same cohort saw a lower mortality rate (10.5% in the Trevo Retriever Registry vs. 15.3% in the interventional arm of the meta-analysis) and a very low rate of symptomatic intracranial haemorrhage (0.6% in the Trevo Retriever Registry vs. 4.4% in the interventional arm of the meta-analysis). The next dataset analysis is planned for after the first 1,000 patients complete follow-up.

The Registry is intended to examine stroke therapy in a real-world setting, including patients with conditions such as carotid disease or uncontrolled diabetes or those with posterior anatomy occlusions. With hundreds of patients included in the Registry, as compared to the much smaller number of patients enrolled in most stroke trials, investigators will have a robust dataset they can use to examine these less-studied patient populations and endovascular techniques.

Upon enrolment of the 1,000th patient into the Registry, Joey English, site principal investigator for the Trevo Retriever Registry and medical director of Neurointerventional Services at the California Pacific Medical Center in San Francisco, USA, commented, “The Trevo Retriever Registry will provide physicians who treat stroke with important information on the benefits of mechanical thrombectomy as well as insights into how to best care for a wide range of patients suffering from this devastating disease. These data will not only be a rich source of knowledge that can be explored for years to come, but will also serve as a platform for generating new studies to further research and improve patient outcomes.”